

BONESUPPORT - FDA Approval – A Major Milestone

Redeye returns following the conference call and chat with management with more flesh on the bones regarding the next steps after the announced FDA approval. We anticipate the first CERAMENT G sales to be recorded in the latter part of H2'22E, and our view on a quick sales ramp-up is further cemented. We raise our Base Case to SEK 77 (70).

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[BONESUPPORT - FDA Approval – A Major Milestone](#)